ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ¼ºñ½º Á¦°ø¾÷üº°, ¼ºñ½ºº°, Ä«Å×°í¸®º°, ÀûÀÀÁõº°, °³¹ß ´Ü°èº°, ±â¾÷ ±Ô¸ðº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Pharmaceutical Regulatory Affairs Market Size, Share & Trends Analysis Report By Service Provider (In-house, Outsourcing), By Service, By Category, By Indication, By Development Stage, By Company Size, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1631487
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 12¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ¼ºÀå°ú µ¿Çâ
±×·£µå ºä ¸®¼Ä¡(Grand View Research, Inc.)ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 143¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â ¿¬Æò±Õ 7.17%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ±ÔÁ¦ ȯ°æÀÇ º¯È¿Í ¸ÂÃãÇü ÀÇ·á, ¹ÙÀÌ¿À½Ã¹Ð·¯, Èñ±ÍÁúȯ Ä¡·áÁ¦ µî ½ÅÈï ºÎ¹®ÀÇ ¼ºÀåÀ̸ç, FDAÀÇ ÀǾàǰ ½ÂÀÎ ÀýÂ÷¿¡ Å« º¯È°¡ ÀϾ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù 21¼¼±â Ä¡·á¹ý¾ÈÀÌ Åë°úµÇ¾î ƯÁ¤ À¯ÇüÀÇ ÀǾàǰ¿¡ ´ëÇÑ FDAÀÇ ½ÂÀÎ ÀýÂ÷°¡ °¡¼Ó鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
FDA´Â 4°¡Áö ÇÁ·Î±×·¥(Accelerated Approval, Priority Review, Fast Track, Breakthrough Therapy)À» ÅëÇØ ÁßÁõ ¹× »ý¸íÀ» À§ÇùÇÏ´Â Áúº´¿¡ ´ëÇÑ ÀǾàǰÀÇ ½É»ç¸¦ ½Å¼ÓÈ÷ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î±×·¥À» ÅëÇØ ÀǾàǰÀº ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ´õ »¡¸® ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿µ±¹¿¡¼´Â ȹ±âÀûÀÎ ½Å¾à¿¡ ´ëÇÑ È¯ÀÚ Á¢±ÙÀ» °¡¼ÓÈÇϱâ À§ÇÑ Á¤ºÎ ÁÖµµ ÀÌ´Ï¼ÅÆ¼ºêÀÎ Accelerated Access Collaborative°¡ ½ÃÀÛµÇ¾î ¿µ±¹¿¡¼ »õ·Î¿î Ä¡·áÁ¦ÀÇ °¡¿ë¼º°ú Á¢±Ù¼ºÀ» Çâ»ó½Ãų °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ º¯È´Â ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí, ÃÖ±Ù ¼¼°è ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ º¯È¿¡ Á¤ÅëÇÑ Á¦¾à ¼ºñ½º Á¦°ø¾÷ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹ÙÀÌ¿À½Ã¹Ð·¯, Èñ±ÍÀǾàǰ, ¸ÂÃãÇü ÀǾàǰ, µ¿¹ÝÁø´Ü, ÀûÀÀÁõ ¼³°è ¹× ±âŸ Á¦Ç° ½ÃÀåÀÇ ¼ºÀå¿¡ µû¶ó ÀÌµé ºÐ¾ßÀÇ ¾à»ç¹ý Àü¹®¼º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¾÷µéÀÌ ´Ù¾çÇÑ »ê¾÷À¸·Î ÁøÃâÇÏ°í ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾à»ç ¾÷¹«¿¡ ´ëÇÑ Àü¹®¼ºÀ» °®Ãá Àü¹® ¼ºñ½º Á¦°ø¾÷ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï °æÁ¦±¹¿¡¼´Â Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿øÀ¸·Î Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ßÀÌ Å©°Ô °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
½ÃÀå °³Ã´À» À§ÇØ ¿©·¯ ±â¾÷ÀÌ Á¦ÈÞ, Àμö, ½ÅÁ¦Ç° °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÇÁ·¹À̾î´Â 2022³â 10¿ù Çѱ¹ÀÇ Á¤Çü¿Ü°ú¿ë ÀÓÇöõÆ® Á¦Á¶È¸»ç¿Í Á¦ÈÞÇÏ¿© °è¾à¿¡ µû¶ó ±ÔÁ¦ ±â±â µî·Ï ¹× ¹ýÀû ´ë¸® ¼ºñ½º¸¦ Á¦°øÇß½À´Ï´Ù. ¶ÇÇÑ, 2022³â 1¿ù Parexel International CorporationÀº Regulatory & Access Consulting OrganizationÀ» ¼³¸³Çß½À´Ï´Ù. ÀÌ Á¶Á÷Àº ÀÓ»ó½ÃÇèÀÇ Ãʱ⠴ܰèºÎÅÍ ¾à»ç Áö¿øÀ» Á¦°øÇϱâ À§ÇØ ¼³¸³µÇ¾ú½À´Ï´Ù.
ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
ºÎ¹®º°·Î´Â Á¦¾à ºÎ¹®ÀÌ 2024³â 55.36% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. Àα¸ Áõ°¡, µµ½ÃÈ, ¾çÁúÀÇ ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ ±¹³» ¼ö¿ä Áõ°¡·Î ÀÎÇØ Çõ½ÅÀûÀÎ ÀǾàǰÀ» °³¹ß ¹× Á¦Á¶ÇÏ´Â Á¦¾à ±â¾÷¿¡ Å« ÀáÀç·ÂÀ» âÃâÇϰí ÀÖ½À´Ï´Ù.
Ä«Å×°í¸®º°·Î´Â ¸»¶ó¸®¾Æ, HIV/AIDS, ºñ°¨¿°¼º Áúȯ°ú °°Àº Áúº´ÀÇ È®»êÀ¸·Î ÀÎÇØ »ý¹°ÇÐÀû Á¦Á¦ ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR 9.07%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀûÀÀÁõº°·Î´Â ¾Ï ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ï´Ù. Á¦¾à»ç ¹× ¹ÙÀÌ¿À Á¦¾à»çÀÇ °·ÂÇÑ ¸é¿ªÇÐ ÆÄÀÌÇÁ¶óÀÎÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2024³â ½ÃÀå Á¡À¯À²Àº ¾Ï ºÐ¾ß°¡ 32.98%·Î °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ¾Ï ¹ßº´·üÀÌ ³ô°í, ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.
°³¹ß ´Ü°èº°·Î´Â ÀÓ»ó ¿¬±¸ ºÎ¹®ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÀÓ»ó½ÃÇè µî·Ï °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀüÀÓ»ó °Ë»ç ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È CAGR 8.40%·Î °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï, CVD, ½Å°æÁúȯ µî ±âÁ¸ ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼ºñ½º Á¦°ø¾÷üº°·Î´Â Á¦¾à ¾Æ¿ô¼Ò½Ì ºÎ¹®ÀÌ 2024³â 59.07%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È 8.76%ÀÇ °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºñ½ºÀÇ ÀαⰡ ³ô¾ÆÁö´Â ¹è°æ¿¡´Â ¾Æ¿ô¼Ò½ÌÀ» ÅëÇØ ÀÇ·á ±â¾÷ÀÌ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óºÎ ½ÃÀå Àü¸Á
º¸Á¶ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
¼ºñ½º °ÝÂ÷ ºÐ¼®
ÀÓ»ó °Ë»ç·® ºÐ¼®, 2024³â
Áö¿ªº° ÀÓ»ó °Ë»ç ÃѼö(2024³â)
ÀÓ»ó °Ë»ç ÃѼö(»óº°)(2024³â)
ÀÓ»ó °Ë»ç ÃѼö(¿¬±¸ µðÀÚÀκ°)(2024³â)
ÁÖ¿ä Ä¡·á ºÐ¾ßº° ÀÓ»ó °Ë»ç ÃѼö(2024³â)
½ÃÀå ºÐ¼® Åø
Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
COVID-19ÀÇ ¿µÇ⠺м®
ÀǾàǰ RA(Regulatory Affairs) ¼ºñ½º¿¡ °üÇÑ º£½ºÆ® ÇÁ·¢Æ¼½º¿Í »ç·Ê ¿¬±¸
Á¦4Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ, 2018-2030³â
»ç³»
¾Æ¿ô¼Ò½Ì
Á¦5Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : ¼ºñ½ºº°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼ºñ½º, 2018-2030³â
±ÔÁ¦ ÄÁ¼³ÆÃ
¹ýÀû ´ë¸®
±ÔÁ¦ ¹®¼ ÁýÇʰú ÃâÆÇ
Á¦Ç° µî·Ï°ú ÀÓ»ó °Ë»ç ½Åû
±âŸ
Á¦6Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : Ä«Å×°í¸®º°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Ä«Å×°í¸®, 2018-2030³â
¾àÁ¦
»ý¹°ÇÐÀû Á¦Á¦
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö
ATMP
¹ÙÀÌ¿À½Ã¹Ð·¯
Á¦7Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : ÀûÀÀÁõº°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÀûÀÀÁõ, 2018-2030³â
Á¾¾çÇÐ
½Å°æÇÐ
½ÉÀ庴ÇÐ
¸é¿ªÇÐ
±âŸ
Á¦8Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : °³¹ß ´Ü°èº°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, °³¹ß ´Ü°è, 2018-2030³â
ÀüÀÓ»ó
ÀÓ»ó ¿¬±¸
½ÃÆÇ ÈÄ ½ÂÀÎ(PMA)
Á¦9Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : ±â¾÷ ±Ô¸ðº°, ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ±â¾÷ ±Ô¸ð, 2018-2030³â
¼Ò
Áß
´ë
Á¦10Àå ÀǾàǰ RA(Regulatory Affairs) ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®
Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
¼¼°è Áö¿ª ½ÃÀå ÇöȲ
½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
³ë¸£¿þÀÌ
³×´ú¶õµå
½ºÀ§½º
½º¿þµ§
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
Àεµ³×½Ã¾Æ
¸»·¹À̽þÆ
½Ì°¡Æ÷¸£
ű¹
´ë¸¸
¶óƾ¾Æ¸Þ¸®Ä«
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
Ä¥·¹
秵»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
Äí¿þÀÌÆ®
ÀÌÁýÆ®
À̽º¶ó¿¤
¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
º¸Ã÷¿Í³ª
³ª¹Ìºñ¾Æ
Áü¹Ùºê¿þ
Àáºñ¾Æ
źÀڴϾÆ
¸£¿Ï´Ù
°¡³ª
³ªÀÌÁö¸®¾Æ
¿ì°£´Ù
¸ð¸®¼Å½º
ÄɳÄ
Á¦11Àå °æÀï ±¸µµ
½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
°æÀï ½ÃÀå Æò°¡ ºÐ¼®(2024³â)
±â¾÷ °³¿ä
Freyr
IQVIA Inc.
ICON plc.
WuXi AppTec(WAI)
Charles River Laboratories International, Inc.
Labcorp Drug Development
Parexel International Corporation
Pharmalex GmbH
Pharmexon
Genpact
ksm
¿µ¹® ¸ñÂ÷
Pharmaceutical Regulatory Affairs Market Growth & Trends:
The global pharmaceutical regulatory affairs market size is expected to reach USD 14.34 billion by 2030, registering a CAGR of 7.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are the changing regulatory landscape and growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs. There have been significant changes to the FDA's drug approval processes. Recently, the 21st Century Cures bill was passed, which is expected to speed up the approval process of the FDA for certain types of drugs.
The FDA has launched four programs-Accelerated Approval, Priority Review, Fast Track, and Breakthrough Therapy-to expedite drug reviews for serious and life-threatening diseases. The medicines under these programs are approved faster by regulatory agencies. In addition, in the UK, the launch of The Accelerated Access Collaborative, a government initiative to fast-track patient access to potential breakthrough medicines, is anticipated to boost the availability and accessibility of novel therapies in the country. These changes in approval processes are expected to drive innovation and increase the demand for regulatory service providers who are well-acquainted with recent changes in approval processes globally.
The demand for regulatory specialization in these fields is anticipated to increase with the growth of the markets for biosimilar, orphan medications, personalized medicines, companion diagnostics, adaptive trial designs, and other products. Demand for specialized service providers with expertise in regulatory affairs is increasing as companies expand into different industries and face a growing burden of regulatory compliance. Government financing has considerably accelerated the development of orphan medications, particularly in industrialized economies.
Several companies are involved in collaborations, acquisitions, and new product development to gain a position in the market. For instance, in October 2022, Freyr partnered with an orthopedic implant manufacturing company in Korea, and as per the agreement, provided it with regulatory device registration and legal representation services. Moreover, in January 2022, Parexel International Corporation formed a Regulatory & Access Consulting Organization. This organization was established to provide regulatory support to clinical studies from the early stages.
Pharmaceutical Regulatory Affairs Market Report Highlights:
In terms of category, the drug segment held the largest revenue share of over 55.36% in 2024. The growing population, increasing urbanization, and rising demand for quality healthcare in the country have created a significant potential for pharmaceutical companies that develop and manufacture innovative drugs
Based on category, the biologics segment is anticipated to register the fastest CAGR of 9.07% over the forecast period owing to the prevalence of diseases such as malaria, HIV/AIDS, and non-communicable diseases
In terms of indication, the oncology segment dominated the market in 2024. The robust immunology pipeline of pharmaceutical and biopharmaceutical companies is anticipated to further boost segment growth
The oncology segment dominated the market in 2024 with the largest revenue share of 32.98%. This can be attributed to the high prevalence of cancer, which is boosting the need for safe and effective treatment options
In terms of development stage, the clinical studies segment held the largest market share in 2024. This can be attributed to the increasing number of clinical trial registrations, which is expected to drive the segment growth
The preclinical segment is projected to grow at the fastest CAGR of 8.40% during the forecast period. Increasing prevalence of existing diseases such as cancer, CVDs, & neurological diseases are factors driving the market growth
In terms of service providers, the outsourced regulatory affairs segment held the largest market share in 2024 at 59.07% and is anticipated to witness the fastest CAGR of 8.76% over the forecast period. The increasing popularity of these services can be attributed to the fact that outsourcing enables healthcare companies to reduce costs, which is a major contributing factor to market growth
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. GVR's Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pharmaceutical Regulatory Affairs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Changing Regulatory Landscape
3.2.1.2. Life Sciences Companies Focusing on Their Core Competencies
3.2.1.3. Economic and Competitive Pressures
3.2.1.4. Demand for the Faster Approval Process for Breakthrough Drugs and Devices
3.2.1.5. Entry of Companies into the Global Market
3.2.1.6. Growth in Emerging Areas such as Personalized Medicine, Biosimilars, and Orphan Drugs
3.2.2. Market Restraint Analysis
3.2.2.1. Risk Associated with Data Security
3.2.2.2. Monitoring Issues and Lack of Standardization
3.3. Service Gap Analysis
3.3.1. Market Opportunities
3.3.1.1. Service Upgrade
3.3.1.2. Technological Advancements
3.3.1.3. Latest Trends
3.3.2. Market Challenges Analysis
3.3.2.1. Analysis Pertaining to Existing Gaps & Shortcomings in the Regulatory Services
3.3.2.2. Bottlenecks Faced by Companies Seeking Regulatory Approvals or Maintaining Compliance
3.4. Clinical Trials Volume Analysis, 2024
3.4.1. Total Number of Clinical Trials, by Region (2024)
3.4.2. Total Number of Clinical Trials, by Phase (2024)
3.4.3. Total Number of Clinical Trials, by Study Design (2024)
3.4.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
3.5. Market Analysis Tools
3.5.1. Porter's Five Forces Analysis
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
3.6. Best Practices and Case Study Pertaining to Regulatory Affairs Services
Chapter 4. Pharmaceutical Regulatory Affairs Market: Service Provider Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
4.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
4.4. In-house
4.4.1. In-house Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Outsourcing
4.5.1. Outsourcing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 5. Pharmaceutical Regulatory Affairs Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
5.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
5.4. Regulatory Consulting
5.4.1. Regulatory Consulting Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Legal Representation
5.5.1. Legal Representation Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Regulatory Writing & Publishing
5.6.1. Regulatory Writing & Publishing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6.2. Writing
5.6.2.1. Writing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6.3. Publishing
5.6.3.1. Publishing Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.7. Product Registration & Clinical Trial Applications
5.7.1. Product Registration & Clinical Trial Applications Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.8. Other Services
5.8.1. Other Services Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 6. Pharmaceutical Regulatory Affairs Market: Category Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
6.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
6.4. Drugs
6.4.1. Drugs Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2. Innovator
6.4.2.1. Innovator Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2.2. Preclinical
6.4.2.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2.3. Clinical
6.4.2.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2.4. Post Market Approval (PMA)
6.4.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.3. Generics
6.4.3.1. Generics Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.3.2. Preclinical
6.4.3.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.3.3. Clinical
6.4.3.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.3.4. Post Market Approval (PMA)
6.4.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Biologics
6.5.1. Biologics Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2. Biotech
6.5.2.1. Biotech Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2.2. Preclinical
6.5.2.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2.3. Clinical
6.5.2.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2.4. Post Market Approval (PMA)
6.5.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3. ATMP
6.5.3.1. ATMP Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3.2. Preclinical
6.5.3.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3.3. Clinical
6.5.3.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3.4. Post Market Approval (PMA)
6.5.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4. Biosimilars
6.5.4.1. Biosimilars Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4.2. Preclinical
6.5.4.2.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4.3. Clinical
6.5.4.3.1. Clinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4.4. Post Market Approval (PMA)
6.5.4.4.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 7. Pharmaceutical Regulatory Affairs Market: Indication Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
7.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Indication, 2018 to 2030 (USD Million)
7.4. Oncology
7.4.1. Oncology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5. Neurology
7.5.1. Neurology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6. Cardiology
7.6.1. Cardiology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7. Immunology
7.7.1. Immunology Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8. Others
7.8.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 8. Pharmaceutical Regulatory Affairs Market: Development Stage Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
8.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Development Stage, 2018 to 2030 (USD Million)
8.4. Preclinical
8.4.1. Preclinical Market Estimates and Forecasts, 2018 to 2030 (USD Million)
8.5. Clinical studies
8.5.1. Clinical Studies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
8.6. Post Market Approval (PMA)
8.6.1. Post Market Approval (PMA) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 9. Pharmaceutical Regulatory Affairs Market: Company Size Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
9.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Company Size, 2018 to 2030 (USD Million)
9.4. Small
9.4.1. Small Market Estimates and Forecasts, 2018 to 2030 (USD Million)
9.5. Medium
9.5.1. Medium Market Estimates and Forecasts, 2018 to 2030 (USD Million)
9.6. Large
9.6.1. Large Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 10. Pharmaceutical Regulatory Affairs Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Global Regional Market Snapshot
10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.4. North America
10.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.4.4. Mexico
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5. Europe
10.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Framework
10.5.2.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Framework
10.5.3.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Framework
10.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Framework
10.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Framework
10.5.6.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.7. Denmark
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Framework
10.5.7.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.8. Norway
10.5.8.1. Key Country Dynamics
10.5.8.2. Competitive Scenario
10.5.8.3. Regulatory Framework
10.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.9. The Netherlands
10.5.9.1. Key Country Dynamics
10.5.9.2. Competitive Scenario
10.5.9.3. Regulatory Framework
10.5.9.4. The Netherlands Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.10. Switzerland
10.5.10.1. Key Country Dynamics
10.5.10.2. Competitive Scenario
10.5.10.3. Regulatory Framework
10.5.10.4. Switzerland Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.5.11. Sweden
10.5.11.1. Key Country Dynamics
10.5.11.2. Competitive Scenario
10.5.11.3. Regulatory Framework
10.5.11.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6. Asia Pacific
10.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.2. Japan
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.3. China
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.4. India
10.6.4.1. Key Country Dynamics
10.6.4.2. Competitive Scenario
10.6.4.3. Regulatory Framework
10.6.4.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.5. Australia
10.6.5.1. Key Country Dynamics
10.6.5.2. Competitive Scenario
10.6.5.3. Regulatory Framework
10.6.5.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.6. South Korea
10.6.6.1. Key Country Dynamics
10.6.6.2. Competitive Scenario
10.6.6.3. Regulatory Framework
10.6.6.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.7. Indonesia
10.6.7.1. Key Country Dynamics
10.6.7.2. Competitive Scenario
10.6.7.3. Regulatory Framework
10.6.7.4. Indonesia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.8. Malaysia
10.6.8.1. Key Country Dynamics
10.6.8.2. Competitive Scenario
10.6.8.3. Regulatory Framework
10.6.8.4. Malaysia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.9. Singapore
10.6.9.1. Key Country Dynamics
10.6.9.2. Competitive Scenario
10.6.9.3. Regulatory Framework
10.6.9.4. Singapore Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.10. Thailand
10.6.10.1. Key Country Dynamics
10.6.10.2. Competitive Scenario
10.6.10.3. Regulatory Framework
10.6.10.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.6.11. Taiwan
10.6.11.1. Key Country Dynamics
10.6.11.2. Competitive Scenario
10.6.11.3. Regulatory Framework
10.6.11.4. Taiwan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.7. Latin America
10.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.7.2. Brazil
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Framework
10.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.7.3. Argentina
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Framework
10.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.7.4. Colombia
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Framework
10.7.4.4. Colombia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.7.5. Chile
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Framework
10.7.5.4. Chile Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8. Middle East
10.8.1. Middle East Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8.2. Saudi Arabia
10.8.2.1. Key Country Dynamics
10.8.2.2. Competitive Scenario
10.8.2.3. Regulatory Framework
10.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8.3. UAE
10.8.3.1. Key Country Dynamics
10.8.3.2. Competitive Scenario
10.8.3.3. Regulatory Framework
10.8.3.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8.4. Kuwait
10.8.4.1. Key Country Dynamics
10.8.4.2. Competitive Scenario
10.8.4.3. Regulatory Framework
10.8.4.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8.5. Egypt
10.8.5.1. Key Country Dynamics
10.8.5.2. Competitive Scenario
10.8.5.3. Regulatory Framework
10.8.5.4. Egypt Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.8.6. Israel
10.8.6.1. Key Country Dynamics
10.8.6.2. Competitive Scenario
10.8.6.3. Regulatory Framework
10.8.6.4. Israel Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9. Africa
10.9.1. Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.2. South Africa
10.9.2.1. Key Country Dynamics
10.9.2.2. Competitive Scenario
10.9.2.3. Regulatory Framework
10.9.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.3. Botswana
10.9.3.1. Key Country Dynamics
10.9.3.2. Competitive Scenario
10.9.3.3. Regulatory Framework
10.9.3.4. Botswana Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.4. Namibia
10.9.4.1. Key Country Dynamics
10.9.4.2. Competitive Scenario
10.9.4.3. Regulatory Framework
10.9.4.4. Namibia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.5. Zimbabwe
10.9.5.1. Key Country Dynamics
10.9.5.2. Competitive Scenario
10.9.5.3. Regulatory Framework
10.9.5.4. Zimbabwe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.6. Zambia
10.9.6.1. Key Country Dynamics
10.9.6.2. Competitive Scenario
10.9.6.3. Regulatory Framework
10.9.6.4. Zambia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.7. Tanzania
10.9.7.1. Key Country Dynamics
10.9.7.2. Competitive Scenario
10.9.7.3. Regulatory Framework
10.9.7.4. Tanzania Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.8. Rwanda
10.9.8.1. Key Country Dynamics
10.9.8.2. Competitive Scenario
10.9.8.3. Regulatory Framework
10.9.8.4. Rwanda Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.9. Ghana
10.9.9.1. Key Country Dynamics
10.9.9.2. Competitive Scenario
10.9.9.3. Regulatory Framework
10.9.9.4. Ghana Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.10. Nigeria
10.9.10.1. Key Country Dynamics
10.9.10.2. Competitive Scenario
10.9.10.3. Regulatory Framework
10.9.10.4. Nigeria Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.11. Uganda
10.9.11.1. Key Country Dynamics
10.9.11.2. Competitive Scenario
10.9.11.3. Regulatory Framework
10.9.11.4. Uganda Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.12. Mauritius
10.9.12.1. Key Country Dynamics
10.9.12.2. Competitive Scenario
10.9.12.3. Regulatory Framework
10.9.12.4. Mauritius Market Estimates and Forecasts, 2018 to 2030 (USD Million)
10.9.13. Kenya
10.9.13.1. Key Country Dynamics
10.9.13.2. Competitive Scenario
10.9.13.3. Regulatory Framework
10.9.13.4. Kenya Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Market Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Competitive Market Assessment Analysis (2024)
11.3. Company Profiles
11.3.1. Freyr
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. IQVIA Inc.
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. ICON plc.
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. WuXi AppTec (WAI)
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Charles River Laboratories International, Inc.
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Labcorp Drug Development
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Parexel International Corporation
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Pharmalex GmbH
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Pharmexon
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Genpact
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
°ü·ÃÀÚ·á